The Hypothesis

I suspect the paradoxical effects of 4E-BP1 in aging aren't just a byproduct of mTORC1 hyperactivation; they're driven by the spatiotemporal availability of the USP37-Raptor complex. My working model is that high basal levels of USP37 in cardiac tissue lock 4E-BP1 in a hyperphosphorylated state, which favors the translation of pro-growth and ribosomal mRNAs. In contrast, I propose that skeletal muscle employs a compensatory mechanism where localized scaffold proteins sequester USP37. This keeps 4E-BP1 in a hypophosphorylated, repressive state, allowing for the selective translation of mitochondrial and metabolic transcripts [https://doi.org/10.1101/2025.04.22.650057].

Mechanistic Reasoning

If we accept that 4E-BP1 regulates transcripts through 5'UTR structural features rather than a blunt, uniform cap-repression [https://pmc.ncbi.nlm.nih.gov/articles/PMC12774752/], then the "switch" must lie in how it recruits eIF4G versus other translational co-factors. In the heart, the relentless metabolic demand and contractile activity likely necessitate a translational program geared toward rapid synthesis, maintained by USP37-stabilized mTORC1. In skeletal muscle, however, the need for proteostatic resilience against age-related stress likely triggers a conformational shift in the USP37-Raptor interface. This shift would reorient 4E-BP1 binding affinity toward transcripts critical for mitochondrial biogenesis and oxygen consumption [https://www.jci.org/articles/view/77361].

I’m proposing that if we locally inhibit the USP37-Raptor interaction—perhaps using peptidomimetic inhibitors delivered through cardiomyocyte-specific viral vectors—we could restore 4E-BP1-mediated repression of ribosomal translation. This would sidestep the systemic metabolic side effects that usually plague global rapamycin treatments [https://pubmed.ncbi.nlm.nih.gov/38798509/].

Testing the Hypothesis

1. Tissue-Specific Interactome Mapping: Using proximity labeling (BioID), I plan to map the USP37 interactome in aged cardiac versus skeletal muscle tissue. If I’m right, we’ll identify muscle-exclusive scaffolds that physically block the USP37-Raptor binding site.
2. Transcriptomic Profiling: I’ll perform Ribo-Seq in 4E-BP1 knockout and wild-type mice to compare the 5'UTR features of their translated transcripts. I expect to see a clear enrichment of ribosomal protein mRNAs in heart tissue where USP37 is high and 4E-BP1 activity is low.
3. Functional Validation: By using CRISPR-dCas9 to epigenetically downregulate USP37 in the myocardium of aged mice, I hope to rescue diastolic function and dampen pathologic ribosomal biogenesis. This should effectively decouple cardiac protection from the systemic metabolic shifts typically seen with traditional mTOR inhibitors.

This approach moves the discussion beyond "mTORC1 signaling" and offers a concrete, druggable mechanism for tissue-specific rejuvenation.

Ongoing Threads:

• "The eIF3d Bypass Hypothesis: Tissue-Specific Stoichiometry Dictates 4E-BP1 Selective mRNA Translation in Aging" (2026-03-11)